{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:11:26Z","timestamp":1788217886790,"version":"build-2803163510"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>The optimal therapy for severe infections caused by vancomycin-resistant <jats:italic>Enterococcus faecium<\/jats:italic> (VREfm) remains unclear, but the combination of linezolid and fosfomycin may be a good choice. The 24-h static-concentration time-kill study (SCTK) was used to preliminarily explore the pharmacodynamics of linezolid combined with fosfomycin against three clinical isolates. Subsequently, a hollow-fibre infection model (HFIM) was used for the first time to further investigate the pharmacodynamic activity of the co-administration regimen against selected isolates over 72 h. To further quantify the relationship between fosfomycin resistance and bacterial virulence in VREfm, the <jats:italic>Galleria mellonella<\/jats:italic> infection model and virulence genes expression experiments were also performed. The results of SCTK showed that the combination of linezolid and fosfomycin had additive effect on all strains. In the HFIM, the dosage regimen of linezolid (12 mg\/L, steady-state concentration) combined with fosfomycin (8 g administered intravenously every 8 h as a 1 h infusion) not only produced a sustained bactericidal effect of 3\u223c4 log<jats:sub>10<\/jats:sub> CFU\/mL over 72 h, but also completely eradicated the resistant subpopulations. The expression of virulence genes was down-regulated to at least 0.222-fold in fosfomycin-resistant strains compared with baseline isolate, while survival rates of <jats:italic>G. mellonella<\/jats:italic> was increased (<jats:italic>G. mellonella<\/jats:italic> survival \u226545% at 72 h). For severe infections caused by VREfm, neither linezolid nor fosfomycin monotherapy regimens inhibited amplification of the resistant subpopulations, and the development of fosfomycin resistance was at the expense of the virulence of VREfm. The combination of linezolid with fosfomycin produced a sustained bactericidal effect and completely eradicated the resistant subpopulations. Linezolid plus Fosfomycin is a promising combination for therapy of severe infections caused by VREfm.<\/jats:p>","DOI":"10.3389\/fmicb.2021.779885","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T14:16:51Z","timestamp":1639491411000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Pharmacodynamics of Linezolid Plus Fosfomycin Against Vancomycin\u2013Resistant Enterococcus faecium in a Hollow Fiber Infection Model"],"prefix":"10.3389","volume":"12","author":[{"given":"Shuaishuai","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaowen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e00342","DOI":"10.1128\/AAC.00342-20","article-title":"Oral fosfomycin treatment for enterococcal urinary tract infections in a dynamic In Vitro model.","volume":"64","author":"Abbott","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fmed.2019.00031","article-title":"Comparative efficacies of linezolid vs. tedizolid in an experimental murine model of vancomycin-resistant enterococcal (VRE) bacteremia.","volume":"6","author":"Abdelhady","year":"2019","journal-title":"Front. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/cpt.2191","article-title":"Evaluation of meropenem-ciprofloxacin combination dosage regimens for the pharmacokinetics of critically ill patients with augmented renal clearance.","volume":"109","author":"Agyeman","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"613800","DOI":"10.3389\/fmicb.2020.613800","article-title":"Genome-wide analysis of Staphylococcus aureus sequence type 72 isolates provides insights into resistance against antimicrobial agents and virulence potential.","volume":"11","author":"Batool","year":"2021","journal-title":"Front. Microbiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1093\/jac\/dky045","article-title":"Elucidation of the pharmacokinetic\/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model.","volume":"73","author":"Bilal","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3389\/fmicb.2018.00572","article-title":"Differential activity of the combination of vancomycin and amikacin on planktonic vs. biofilm-growing Staphylococcus aureus bacteria in a hollow fiber infection model.","volume":"9","author":"Broussou","year":"2018","journal-title":"Front. Microbiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1128\/AAC.04629-14","article-title":"Emergence of polymyxin B resistance influences pathogenicity in Pseudomonas aeruginosa mutators.","volume":"59","author":"Bulman","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2217\/fmb-2018-0303","article-title":"ZTI-01 (fosfomycin for injection) in the treatment of hospitalized patients with complicated urinary tract infections.","volume":"14","author":"Burgos","year":"2019","journal-title":"Future Microbiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1517\/17425255.2016.1166204","article-title":"Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones.","volume":"12","author":"Cattaneo","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol"},{"key":"B10","year":"2019","journal-title":"Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Ninth Informational Supplement (M100)."},{"key":"B11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3389\/fmicb.2019.00311","article-title":"Optimization and characterization of a Galleria mellonella larval infection model for virulence studies and the evaluation of therapeutics against Streptococcus pneumoniae.","volume":"10","author":"Cools","year":"2019","journal-title":"Front. Microbiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e01815","DOI":"10.1128\/AAC.01815-17","article-title":"Evaluation of activity and emergence of resistance of polymyxin B and ZTI-01 (fosfomycin for injection) against KPC-producing Klebsiella pneumoniae.","volume":"62","author":"Diep","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B13","first-page":"8","article-title":"New microbiological aspects of fosfomycin.","volume":"32","author":"D\u00edez-Aguilar","year":"2019","journal-title":"Rev. Esp. Quimioter"},{"key":"B14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/antibiotics6040024","article-title":"Fosfomycin: pharmacological, clinical and future perspectives.","volume":"6","author":"Dijkmans","year":"2017","journal-title":"Antibiotics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/j.1469-0691.2008.01993.x","article-title":"A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.","volume":"14","author":"Drago","year":"2008","journal-title":"Clin. Microbiol. Infect."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e01682","DOI":"10.1128\/AAC.01682-18","article-title":"The combination of fosfomycin plus meropenem is synergistic for Pseudomonas aeruginosa PAO1 in a hollow-fiber infection model.","volume":"62","author":"Drusano","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijantimicag.2018.09.013","article-title":"Resistance to fosfomycin: mechanisms, frequency and clinical consequences.","volume":"53","author":"Falagas","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin.","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e00008","DOI":"10.1128\/MMBR.00008-19","article-title":"Adaptation to adversity: the intermingling of stress tolerance and pathogenesis in enterococci.","volume":"83","author":"Gaca","year":"2019","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.mib.2017.11.030","article-title":"Evolution of virulence in Enterococcus faecium, a hospital-adapted opportunistic pathogen.","volume":"41","author":"Gao","year":"2018","journal-title":"Curr. Opin. Microbiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"101643","DOI":"10.1016\/j.pdpdt.2019.101643","article-title":"Modulation of virulence in Enterococcus faecalis cells surviving antimicrobial photodynamic inactivation with reduced graphene oxide-curcumin: an ex vivo biofilm model.","volume":"29","author":"Ghorbanzadeh","year":"2020","journal-title":"Photodiagnosis. Photodyn. Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"523","DOI":"10.20471\/acc.2020.59.03.17","article-title":"Vancomycin-resistant Enterococcus faecium COLONIZATION and Clostridium difficile infection in a HEMATOLOGIC patient.","volume":"59","author":"Goi\u0107-Bari\u0161i\u0107","year":"2020","journal-title":"Acta Clin. Croat."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.3201\/eid2311.171130","article-title":"High-level fosfomycin resistance in vancomycin-resistant Enterococcus faecium.","volume":"23","author":"Guo","year":"2017","journal-title":"Emerg. Infect. Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.2147\/DDDT.S164515","article-title":"Linezolid: a review of its properties, function, and use in critical care.","volume":"12","author":"Hashemian","year":"2018","journal-title":"Drug Des. Devel. Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.2147\/IDR.S208298","article-title":"Vancomycin-resistant enterococcal infection in a Thai university hospital: clinical characteristics, treatment outcomes, and synergistic effect.","volume":"12","author":"Hemapanpairoa","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"B26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40121-015-0092-8","article-title":"Adverse events associated with fosfomycin use: review of the literature and analyses of the FDA adverse event reporting system database.","volume":"4","author":"Iarikov","year":"2015","journal-title":"Infect. Dis. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1128\/AAC.00984-09","article-title":"In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and vancomycin.","volume":"53","author":"Jacqueline","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"605962","DOI":"10.3389\/fmicb.2020.605962","article-title":"Synergistic combination of linezolid and fosfomycin closing each other\u2019s mutant selection window to prevent enterococcal resistance.","volume":"11","author":"Jiang","year":"2021","journal-title":"Front. Microbiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.3390\/cells9112397","article-title":"Advances and prospects in vaccine development against enterococci.","volume":"9","author":"Kalfopoulou","year":"2020","journal-title":"Cells"},{"key":"B30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/jac\/dkr466","article-title":"Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens.","volume":"67","author":"Karageorgopoulos","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/jof4030113","article-title":"The use of Galleria mellonella larvae to identify novel antimicrobial agents against fungal species of medical Interest.","volume":"4","author":"Kavanagh","year":"2018","journal-title":"J. Fungi"},{"key":"B32","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/s12917-019-2221-1","article-title":"Methicillin-resistant Staphylococcus aureus and glycopeptide-resistant enterococci in fecal samples of birds from South-Eastern Poland.","volume":"15","author":"Kutkowska","year":"2019","journal-title":"BMC Vet. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1186\/s40064-016-2870-5","article-title":"Multiplex PCR based genotypic characterization of pathogenic vancomycin resistant Enterococcus faecalis recovered from an Indian river along a city landscape.","volume":"5","author":"Lata","year":"2016","journal-title":"Springerplus"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1128\/AAC.02657-15","article-title":"Sequential evolution of vancomycin-intermediate resistance alters virulence in Staphylococcus aureus: pharmacokinetic\/pharmacodynamic targets for vancomycin exposure.","volume":"60","author":"Lenhard","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B35","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2217\/fmb-2019-0333","article-title":"Global priority pathogens: virulence, antimicrobial resistance and prospective treatment options.","volume":"15","author":"M Campos","year":"2020","journal-title":"Future Microbiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s10096-014-2285-6","article-title":"Testing the mutant selection window hypothesis in vitro and in vivo with Staphylococcus aureus exposed to fosfomycin.","volume":"34","author":"Mei","year":"2015","journal-title":"Eur. J. Clin. Microbiol. Infec"},{"key":"B37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ijantimicag.2019.04.010","article-title":"Efficacy of oritavancin alone and in combination against vancomycin-susceptible and -resistant enterococci in an in-vivo Galleria mellonella survival model.","volume":"54","author":"Meyer","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1124\/pr.111.005769","article-title":"Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs.","volume":"65","author":"Nielsen","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1128\/AAC.02583-12","article-title":"Activities of fosfomycin and rifampin on planktonic and adherent Enterococcus faecalis strains in an experimental foreign-body infection model.","volume":"58","author":"Oliva","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B40","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3390\/jcm8070934","article-title":"Treatment options for colistin resistant Klebsiella pneumoniae: present and future.","volume":"8","author":"Petrosillo","year":"2019","journal-title":"J. Clin. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e02213","DOI":"10.1128\/AAC.02213-20","article-title":"Activity of fosfomycin and amikacin against fosfomycin-heteroresistant Escherichia coli strains in a hollow-fiber infection model.","volume":"65","author":"Portillo-Calder\u00f3n","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B42","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ijmm.2017.09.019","article-title":"Biological cost of fosfomycin resistance in Escherichia coli in a murine model of urinary tract infection.","volume":"307","author":"Pourbaix","year":"2017","journal-title":"Int. J. Med. Microbiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13756-017-0291-z","article-title":"Economic burden of nosocomial infections caused by vancomycin-resistant enterococci.","volume":"7","author":"Puchter","year":"2018","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.2147\/IDR.S219117","article-title":"Pharmacodynamics of linezolid-plus-fosfomycin against vancomycin-susceptible and -resistant enterococci In Vitro and In Vivo of a Galleria mellonella larval infection model.","volume":"12","author":"Qi","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3390\/microorganisms8081118","article-title":"Enterococci, from harmless bacteria to a pathogen.","volume":"8","author":"Ramos","year":"2020","journal-title":"Microorganisms"},{"key":"B46","first-page":"19","article-title":"Deciphering pharmacokinetics and pharmacodynamics of fosfomycin.","volume":"32","author":"Rodr\u00edguez-Gasc\u00f3n","year":"2019","journal-title":"Rev. Esp. Quimioter."},{"key":"B47","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1128\/AAC.49.11.4448-4454.2005","article-title":"Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles.","volume":"49","author":"Sauermann","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e1007525","DOI":"10.1371\/journal.pgen.1007525","article-title":"Epistatic control of intrinsic resistance by virulence genes in Listeria.","volume":"14","author":"Scortti","year":"2018","journal-title":"PLoS Genet."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e01763","DOI":"10.1128\/AAC.01763-16","article-title":"Pharmacodynamics of aerosolized fosfomycin and amikacin against resistant clinical isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a hollow-fiber infection model: experimental basis for combination therapy.","volume":"61","author":"Sime","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B50","doi-asserted-by":"publisher","first-page":"5716","DOI":"10.1128\/AAC.00687-16","article-title":"Fosfomycin enhances the activity of daptomycin against vancomycin-resistant enterococci in an In Vitro pharmacokinetic-pharmacodynamic model.","volume":"60","author":"Snyder","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B51","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.bjid.2015.11.011","article-title":"Incidence of virulence determinants in clinical Enterococcus faecalis and Enterococcus faecium isolates collected in Bulgaria.","volume":"20","author":"Strateva","year":"2016","journal-title":"Braz. J. Infect. Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.3389\/fmicb.2017.01541","article-title":"Identification of novel conjugative plasmids with multiple copies of fosB that confer high-level fosfomycin resistance to vancomycin-resistant enterococci.","volume":"8","author":"Sun","year":"2017","journal-title":"Front. Microbiol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"816","DOI":"10.3390\/microorganisms8060816","article-title":"Probiotic cocktail identified by microbial network analysis inhibits growth, virulence gene expression, and host cell colonization of vancomycin-resistant enterococci.","volume":"8","author":"Sun","year":"2020","journal-title":"Microorganisms"},{"key":"B54","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3389\/fcimb.2020.00274","article-title":"Determining the genetic characteristics of resistance and virulence of the \u201cepidermidis cluster group\u201d through pan-genome analysis.","volume":"10","author":"Sun","year":"2020","journal-title":"Front. Cell. Infect. Microbiol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3389\/fphar.2020.00473","article-title":"Cajanin stilbene acid inhibited vancomycin-resistant Enterococcus by inhibiting phosphotransferase system.","volume":"11","author":"Tan","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1080\/21505594.2015.1135289","article-title":"Galleria mellonella infection models for the study of bacterial diseases and for antimicrobial drug testing.","volume":"7","author":"Tsai","year":"2016","journal-title":"Virulence"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1093\/jac\/dks201","article-title":"Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations.","volume":"67","author":"Tsuji","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"B58","doi-asserted-by":"publisher","first-page":"6024","DOI":"10.1128\/AAC.02310-13","article-title":"Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model.","volume":"58","author":"VanScoy","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B59","doi-asserted-by":"publisher","first-page":"5141","DOI":"10.1128\/AAC.00355-16","article-title":"Relationship between fosfomycin exposure and amplification of Escherichia coli subpopulations with reduced susceptibility in a hollow-fiber infection model.","volume":"60","author":"VanScoy","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B60","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3390\/antibiotics9090565","article-title":"Vancomycin-resistant enterococci (VRE) in Nigeria: the first systematic review and meta-analysis.","volume":"9","author":"Wada","year":"2020","journal-title":"Antibiotics"},{"key":"B61","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jmii.2017.08.025","article-title":"Clinical characteristics and treatment outcomes of vancomycin-resistant Enterococcus faecium bacteremia.","volume":"51","author":"Ye","year":"2018","journal-title":"Microbiol. Immunol. Infect."},{"key":"B62","doi-asserted-by":"publisher","first-page":"8912039","DOI":"10.1155\/2018\/8912039","article-title":"Intravenous fosfomycin: an assessment of its potential for use in the treatment of systemic infections in Canada.","volume":"2018","author":"Zhanel","year":"2018","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jgar.2019.08.006","article-title":"Molecular mechanisms and epidemiology of fosfomycin resistance in enterococci isolated from patients at a teaching hospital in China, 2013-2016.","volume":"20","author":"Zhang","year":"2020","journal-title":"J. Glob. Antimicrob. Resist"},{"key":"B64","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40360-020-0396-5","article-title":"Levofloxacin-ceftazidime administration regimens combat Pseudomonas aeruginosa in the hollow-fiber infection model simulating abnormal renal function in critically ill patients.","volume":"21","author":"Zhao","year":"2020","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1093\/jac\/dkx070","article-title":"Pharmacodynamics of colistin and fosfomycin: a \u2018treasure trove\u2019 combination combats KPC-producing Klebsiella pneumoniae.","volume":"72","author":"Zhao","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B66","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jgar.2020.03.027","article-title":"Molecular characteristics and risk factors associated with linezolid-resistant Enterococcus faecalis infection in Southwest China.","volume":"22","author":"Zou","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.779885\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T14:16:57Z","timestamp":1639491417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.779885\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,14]]},"references-count":66,"alternative-id":["10.3389\/fmicb.2021.779885"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2021.779885","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,14]]},"article-number":"779885"}}